EGFR-Targeted Therapy in NSCLC Leptomeningeal Carcinomatosis - priME Oncology
Expert Perspectives
Expert Perspectives

EGFR-Targeted Therapy in NSCLC Leptomeningeal Carcinomatosis

Not a member of My prIME? Join now for instant access.

Enhance your understanding of leptomeningeal carcinomatosis in non-small cell lung cancer (NSCLC) with key points and downloadable slides from the experts. Each faculty member summarizes their presentation from the live meeting and provides insights and commentary. Topics include incidence of leptomeningeal carcinomatosis, limitations of traditional therapies, and the efficacy of EGFR-targeted agents in this patient setting.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

0.25 AMA PRA Category 1 Credit™

Release Date

Release Date

Dec 21, 2017

Expiration Date

Dec 21, 2018

  • Manmeet Ahluwalia, MD, FACPCleveland Clinic
    Cleveland, Ohio, United States
  • Jeremy Rudnick, MDCedars-Sinai Medical Center
    Los Angeles, California, United States
  • Heather Wakelee, MDStanford University
    Stanford, California, United States

Introduction
Manmeet Ahluwalia, MD, FACP

Leptomeningeal carcinomatosis in NSCLC: The scope of the challenge
Jeremy Rudnick, MD 

Examining strategies for leptomeningeal carcinomatosis in EGFR-mutant NSCLC
Heather Wakelee, MD

This educational activity is specifically designed to meet the needs of neuro-oncologists, medical oncologists, and other healthcare professionals providing care to patients with leptomeningeal carcinomatosis in NSCLC.

After successful completion of this educational activity, participants should be able to:

  • Evaluate the efficacy of EGFR TKIs in the treatment of leptomeningeal carcinomatosis in NSCLC in recent trials
  • Identify and manage potential treatment-related adverse events associated with EGFR TKIs

This educational activity is supported by a grant from AstraZeneca.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

EGFR-Targeted Therapy in NSCLC Leptomeningeal Carcinomatosis - prIME Oncology

prIME Oncology designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This enduring activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

Links to the posttest are available on the video player pages.

In order to receive credit, participants must successfully complete the online posttest with 75% or higher.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Ahluwalia disclosed that he has received consulting fees from AbbVie, AstraZeneca, Bristol-Myers Squibb, CBT Pharmaceuticals, Datar Genetics, Kadmon Pharmaceuticals, and Monteris Medical. He has also disclosed independent contracting for AbbVie, AstraZeneca, Bristol-Myers Squibb, Merck, Novartis, Novocure, and Tracon Pharmaceuticals. He has also received honorarium as an editor for Elsevier. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Rudnick disclosed that he has received honoraria for participation in a promotional speaker’s bureau from Novocure. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Wakelee disclosed that she has received consulting fees from or has been a consultant for ACEA, Genentech (uncompensated), Helsinn, Peregrine, and Pfizer. She has also received research support from AstraZeneca/MedImmune, Bristol-Myers Squibb, Celgene, Clovis, Exelixis, Genentech/Roche, Gilead, Lilly, Novartis, Pfizer, Pharmacyclics, and Xcovery. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

The employees of prIME Oncology have disclosed:

  • Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Amy Furedy, RN, OCN (scientific content reviewer/planner) – no relevant financial relationships
  • Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.